NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
(NCCN GUIDELINES®) RECOMMENDATIONS10*

Initial Systemic Therapy

All Histologies
Advanced or Metastatic Non–Small Cell Lung Cancer (mNSCLC)

Albumin-bound paclitaxel
(ABRAXANE)
+ carboplatin

NCCN

Category 1a
Albumin-bound paclitaxel (ABRAXANE) + carboplatin is a treatment option included in the NCCN Guidelines® for Non-Small Cell Lung Cancer with a Category 1 recommendation for the first-line treatment of metastatic squamous cell carcinoma and nonsquamous NSCLC (PS 0-1)b

  • *For additional considerations and treatment options, see NCCN.org.
  • a Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
  • b EGFR, ALK, ROS1, BRAF negative or unknown, PD-L1 <50% or unknown, treatment option for patients with contraindications to the addition of pembrolizumab or atezolizumab.
  • ALK=anaplastic lymphoma kinase; BRAF=B-Raf proto-oncogene; EGFR=epidermal growth factor receptor; NCCN=National Comprehensive Cancer Network;PD-L1=programmed death-ligand 1; PS=performance status; ROS1=c-ros oncogene 1.
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL